Boston Millennia Partners
Boston Millennia Partners (BMP) is a Boston-based venture and growth equity firm focused on healthcare companies. For over 30 years BMP has invested in early and growth-stage healthcare IT, technology-enabled services, biopharma and medical device companies, using an active, hands-on ‘Core Company’ buy-and-build strategy to accelerate scale and strategic exits.
Industries
Nr. of Employees
small (1-50)
Boston Millennia Partners
50 Milk Street, Boston, MA 02108 (Mailing address: 71 Commercial St, #301, Boston, MA 02109)
Portfolio
Developed a wireless pulmonary artery sensor; acquired by St. Jude Medical for $450,000,000 (05/28/2014). BMP provided clinical trial design, capital raising and FDA navigation support.
#Medical device (remote monitoring for heart failure)
BMP was an early institutional investor and co-founder partner; Collegium completed IPO (05/07/2015, $70,000,000) and developed Xtampza ER with FDA approval processes.
#Specialty pharmaceuticals / drug reformulation
BMP invested in GlycoFi's first institutional round (2002), served on the board, helped recruit a CEO, raised $30M in additional financing; GlycoFi was acquired by Merck for $400,000,000 (2006) yielding ~10x return for BMP investors.
#Biotechnology / protein expression and glycosylation
Supported company growth, helped complete two Core acquisitions, assisted with IPO (Feb 1997) and product launch (Campath); acquired by Genzyme for $1 billion (2004).
#Biopharma / oncology
Develops minimally invasive joint resurfacing implant systems; markets in U.S. and multiple international markets.
#Orthopedic devices
Series G financing $40,000,000 (08/26/2014).
#Logistics and supply-chain technology
Developed a wireless pulmonary artery sensor; acquired by St. Jude Medical for $450,000,000 (05/28/2014). BMP provided clinical trial design, capital raising and FDA navigation support.
#Medical device (remote monitoring for heart failure)
BMP was an early institutional investor and co-founder partner; Collegium completed IPO (05/07/2015, $70,000,000) and developed Xtampza ER with FDA approval processes.
#Specialty pharmaceuticals / drug reformulation
BMP invested in GlycoFi's first institutional round (2002), served on the board, helped recruit a CEO, raised $30M in additional financing; GlycoFi was acquired by Merck for $400,000,000 (2006) yielding ~10x return for BMP investors.
#Biotechnology / protein expression and glycosylation
Supported company growth, helped complete two Core acquisitions, assisted with IPO (Feb 1997) and product launch (Campath); acquired by Genzyme for $1 billion (2004).
#Biopharma / oncology
Develops minimally invasive joint resurfacing implant systems; markets in U.S. and multiple international markets.
#Orthopedic devices
Series G financing $40,000,000 (08/26/2014).
#Logistics and supply-chain technology